PHATHOM PHARMACEUTICALS INC (PHAT)

US71722W1071 - Common Stock

7.61  +0.16 (+2.15%)

After market: 7.61 0 (0%)

PHATHOM PHARMACEUTICALS INC

NASDAQ:PHAT (12/23/2024, 8:25:22 PM)

After market: 7.61 0 (0%)

7.61

+0.16 (+2.15%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%-73.68%
Sales Q2Q%N/A
CRS8.53
6 Month-26.12%
Overview
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Ins Owners4.18%
Inst Owners79.35%
Market Cap520.37M
Shares68.38M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts84.29
Short Float %27.49%
Short Ratio10.44
IPO10-25 2019-10-25
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

PHAT Daily chart

Company Profile

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey and currently employs 452 full-time employees. The company went IPO on 2019-10-25. The firm is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s pipeline product candidate, VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.

Company Info

PHATHOM PHARMACEUTICALS INC

100 Campus Drive, Suite 102

Florham Park NEW JERSEY 07932

P: 18777428466

CEO: Terrie Curran

Employees: 452

Website: https://www.phathompharma.com/

PHAT News

News Image13 days ago - Phathom PharmaceuticalsPhathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets
News Image13 days ago - Phathom PharmaceuticalsPhathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

Citizen Petition seeks correction of expiration date for New Chemical Entity (NCE) exclusivity on VOQUEZNA (vonoprazan) tablets Orange Book listingsPhathom...

News Imagea month ago - Market News VideoPhathom Pharmaceuticals is Now Oversold (PHAT)
News Imagea month ago - Market News VideoPHAT Crosses Below Key Moving Average Level
News Image2 months ago - Phathom PharmaceuticalsPhathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
News Image2 months ago - Phathom PharmaceuticalsPhathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

Net revenues of $16.4 million reported for the third quarter 2024 compared to $7.3 million in the second quarter 2024, over 120% sequential quarterly...

PHAT Twits

Here you can normally see the latest stock twits on PHAT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example